Transient hyperglycemia during childhood acute lymphocytic leukemia chemotherapy: An old event revisited

Clinical Advances in Hematology and Oncology

Volumn 7, Issue 7, 2009, Pages 465-472

  Spinola Castro, Angela Maria ^a   Siviero Miachon, Adriana Aparecida ^a   Andreoni, Solange ^a   Tosta Hernandez, Patricia Debora Cavalcanti ^a   Macedo, Carla Renata Pacheco Donato ^a   Lee, Maria Lucia de Martino ^a  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Acute drug therapy; Asparaginase; Glucocorticoid; Hyperglycemia; Insulin; Leukemia; Lymphocytic

Indexed keywords

ASPARAGINASE; DAUNORUBICIN; DEXAMETHASONE; METHYLPREDNISOLONE; PREDNISONE; VINCRISTINE;

ACUTE LYMPHOCYTIC LEUKEMIA; ADOLESCENT; ADVERSE OUTCOME; AMYLASE BLOOD LEVEL; ARTICLE; BLOOD GLUCOSE MONITORING; BODY MASS; CANCER CHEMOTHERAPY; CHILD; CHILDHOOD LEUKEMIA; CLINICAL ARTICLE; CLINICAL EVALUATION; COMPARATIVE STUDY; DOSE RESPONSE; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; INSULIN TREATMENT; MALE; OBESITY; PANCREATITIS; REMISSION; RISK FACTOR;

ADOLESCENT; AMYLASES; ANTINEOPLASTIC AGENTS; BLOOD GLUCOSE; BODY MASS INDEX; CHILD; CHILD, PRESCHOOL; FEMALE; GLUCOCORTICOIDS; HUMANS; HYPERGLYCEMIA; INFANT; MALE; NEOPLASM RECURRENCE, LOCAL; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; REMISSION INDUCTION; RETROSPECTIVE STUDIES;

EID: 70349499015     PISSN: 15430790     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Bhatia S, Landier W. Evaluating survivors of pediatric cancer. Cancer J. 2005;11: 340-354.
2. Venkatraman R, Jayashree M, Singhi S, et al. Hyperglycemic hyperosmolar nonketotic syndrome in a child with acute lymphoblastic leukemia undergoing induction chemotherapy: Case report. J Pediatr Hematol/ Oncol. 2005;27: 234-235.
3. Hsu YJ, Chen YC, Ho CL, et al. Diabetic ketoacidosis and persistent hyperglycemia as long-term complications of L-asparaginase-induced pancreatitis. Zhonghua Yi Xue Za Zhi (Taipei). 2002;65: 441-445.
4. Cetin M, Yetgin S, Kara A, et al. Hyperglycemia, ketoacidosis and other complications of L-asparaginase in children with acute lymphoblastic leukemia. J Med. 1994;25: 219-229.
5. Roberson JR, Raju S, Shelso J, et al. Diabetic ketoacidosis during therapy for pediatric acute lymphoblastic leukemia. Pediatr Blood Cancer. 2008;50:1207-1212.
6. Howard SC, Pui CH. Endocrine complications in pediatric patients with acute lymphoblastic leukemia. Blood Rev. 2002;16:225-243.
7. Weiser MA, Cabanillas ME, Konopleva M, et al. Relation between the duration of remission and hyperglycemia during induction chemotherapy for acute lymphocytic leukemia with a hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone/ methotrexate-cytarabine regimen. Cancer. 2004; 100:1179-1185.
8. Baillargeon J, Langevin AM, Mullins J, et al. Transient hyperglycemia in Hispanic children with acute lymphoblastic leukemia. Pediatr Blood Cancer. 2005;45:960-963.
9. Wang YJ, Chu HY, Shu SG, et al. Hyperglycemia induced by chemotherapeutic agents used in acute lymphoblastic leukemia: Report of three cases. Zhonghua Yi Xue Za Zhi (Taipei). 1993;51:457-461.
10. Iyer RS, Rao SR, Pai S, et al. L-asparaginase related hyperglycemia. Indian J Cancer. 1993;30:72-76.
11. Carpentieri U, Balch MT. Hyperglycemia associated with the therapeutic use of L-asparaginase: Possible role of insulin receptors. J Pediatr. 1978;93:775-778.
12. Rovira A, Cordido F, Vecilla C, et al. Study of beta-cell function and erythrocyte insulin receptors in a patient with diabetic ketoacidosis associated with L-asparaginase therapy. Acta Paediatr Scand. 1986;75:670-671.
13. Knoderer HM, Robarge J, Flockhart DA. Predicting asparaginase-associated pancreatitis. Pediatr Blood Cancer. 25, 2007;49:634-639.
14. Laugel V, Escande B, Entz-Werle N, et al. Severe acute pancreatitis in children receiving asparaginase: Multicenter retrospective study. Arch Pediatr. 2005;12: 34-41.
15. Belgaumi AF, Al-Bakrah M, Al-Mahr M, et al. Dexamethasone-associated toxicity during induction chemotherapy for childhood acute lymphoblastic leukemia is augmented by concurrent use of daunomycin. Cancer. 2003;97:2898-2903.
16. Yetgin S, Yalcin SS, Ozbek N. Clinical value of glycated hemoglobin and fructosamine in the long-term glycemic control of children with acute lymphoblastic leukemia. Acta Paediatr Jpn. 1998;40:52-56.
17. Sonabend RY, McKay SV, Okcu MF, et al. Hyperglycemia during induction therapy is associated with increased infectious complications in childhood acute lymphocytic leukemia. Pediatr Blood Cancer. 2008;51:387-392.
18. Lowas SR, Marks D, Malempati S. Prevalence of transient hyperglycemia during induction chemotherapy for pediatric acute lymphoblastic leukemia. Pediatr Blood Cancer. 2009;52:814-818.
19. Brandalise S, Odone V, Pereira W, et al. Treatment results of three consecutive Brazilian cooperative childhood ALL protocols: GBTLI-80, GBTLI-82 and -85. ALL Brazilian Group. Leukemia. 1993;7 (suppl 2):S142-S145.
20. Marshall WA, Tanner JM. Variations in pattern of pubertal changes in girls. Arch Dis Child. 1969;44:291-303.
21. Marshall WA, Tanner JM. Variations in the pattern of pubertal changes in boys. Arch Dis Child. 1970;45:13-23.
22. National Center for Health Statistics (NCHS) [homepage on the Internet]. 2000 CDC Growth Charts: United States [updated 04 June 2009]. Accessed on 07 June 2009. Available on http://www.cdc.gov/growthcharts.
23. Ogden CL, Carroll MD, Curtin LR, et al. Prevalence of overweight and obesity in the United States, 1999-2004. JAMA. 2006;295:1549-1555.
24. Reilly JJ, Ventham JC, Newell J, et al. Risk factors for excess weight gain in children treated for acute lymphoblastic leukaemia. Int J Obes Relat Metab Disord. 2000;24:1537-1541.
25. American Diabetes Association. Type 2 diabetes in children and adolescents. Pediatrics. 2000;105:671-680.
26. Harish K, Dharmalingam M, Himanshu M. Study protocol: Insulin and its role in cancer. BMC Endocr Disord. 2007;7:10.
27. Neville KA, Cohn RJ, Steinbeck KS, et al. Hyperinsulinemia, impaired glucose tolerance, and diabetes mellitus in survivors of childhood cancer: Prevalence and risk factors. J Clin Endocrinol Metab. 2006;91:4401-4407.
28. Mohn A, DiMarzio A, Capanna R, et al. Persistence of impaired pancreatic β-cell function in children treated for acute lymphoblastic leukaemia. Lancet. 2004;363:127-128.
29. Kourti M, Tragiannidis A, Makedou A, et al. Metabolic syndrome in children and adolescents with acute lymphoblastic leukemia after the completion of chemotherapy. J Pediatr Hematol/Oncol. 2005;27:499-501.
30. Hoffmeister PA, Storer BE, Sanders JE. Diabetes mellitus in long-term survivors of pediatric hematopoietic cell transplantation. J Pediatr Hematol/Oncol. 2004;26:81-90.
31. Siviero-Miachon AA, Spinola-Castro AM, Guerra-Junior G. Detection of metabolic syndrome features among childhood cancer survivors: A target to prevent disease. Vasc Health Risk Manag. 2008;4:825-836.
32. Ridgway D, Neerhout RC, Bleyer A. Attenuation of asparaginase-induced hyperglycemia after substitution of the Erwinia carotovora for the Escherichia coli enzyme preparation. Cancer. 1989;63:561-563.
33. Liang DC, Hung IJ, Yang CP, et al. Unexpected mortality from the use of E. coli L-asparaginase during remission induction therapy for childhood acute lymphoblastic leukemia: A report from the Taiwan Pediatric Oncology Group. Leukemia. 1999;13:155-160.
34. Hak LJ, Relling MV, Cheng C, et al. Asparaginase pharmacodynamics differ by formulation among children with newly diagnosed acute lymphoblastic leukemia. Leukemia. 2004;18:1072-1077.
35. Müller HJ, Löning L, Horn A, et al. Pegylated asparaginase (Oncospar) in children with ALL: Drug monitoring in reinduction according to the ALL/NHL-BFM 95 protocols. Br J Haematol. 2000;110:379-384.
36. Karabulut R, Sonmez K, Afsarlar C, et al. Pancreas pseudocyst associated with L-asparaginase treatment: A case report. Acta Chir Belg. 2005;105:667-669.
37. Top PC, Tissing WJ, Kuiper JW, et al. L-asparaginase-induced severe necrotizing pancreatitis successfully treated with percutaneous drainage. Pediatr Blood Cancer. 2005;44:95-97.
38. Pui CH, Burghen GA, Bowman WP, et al. Risk factors for hyperglycemia in children with leukemia receiving L-asparaginase and prednisone. J Pediatr. 1981;99:46-50.